NL-OMON26812招募中不适用
ymphnodes with and without Alemtuzumab to Measure Broad Alloreactivity against Donor Antigens
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •In order to be eligible to participate in this study, a subject must meet the following criteria:
- •-Adult patients receiving a deceased or living kidney transplant in the Erasmus Medical Center Rotterdam, The Netherlands and:
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •-ABO-compatible HLA identical living-related transplant recipients.
研究者
相似试验
已完成
不适用
ymphnodes with and without Alemtuzumab to Measure Broad Alloreactivity against Donor Antigensniertransplantatierejection of kidney allograft10038430NL-OMON42749Interne Geneeskunde, sector Nefrologie en Niertransplantatie100
招募中
不适用
Samenstelling van lymfklieren en het risico op afstoting na niertransplantatie.niertransplantatie, kidney transplantationlymfklieren, lymph nodesalemtuzumaballoreactiviteit, alloreactivityveroudering immuunsysteem, ageing of the immune systemT-folliculaire helper cellen, T-follicular helper cellsNL-OMON22565Erasmus Medical Center100
进行中（未招募）
不适用
Therapy with Alemtuzumab (Mabcampath) in patients with acute Lymphoblastic leukemia either refractoy or in relapse. Phase II, multicentric, not randomized study.EUCTR2004-001739-53-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
进行中（未招募）
1 期
CLARET: CLL Levels following Alemtuzumab in Responders to Early Therapy: A randomised, phase III trial to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CLL) who have responded to previous therapy. - CLARET Version 3.0Chronic lymphocytic leukaemia (CLL).MedDRA version: 15.0 Level: PT Classification code 10008958 Term: Chronic lymphocytic leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003012-35-GBeeds Teaching Hospitals NHS Trust116
进行中（未招募）
不适用
A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaEUCTR2010-024389-23-SEDepartment of Hematology30